Abstract
Tat is a viral protein secreted from HIV infected cells and extra cellular Tat is suspected to prevent destruction of HIV infected cells from cells of the cellular immunity. The effect of anti retroviral therapy (ART) on Tat secretion has never been investigated. In this study, we tested for antibody reactivity against Tat variants representative of the main HIV subtypes in HIV positive patients receiving ART with undetectable viral loads ( < 40 copies/mL) over the course of one year with a blood sampling every three months. For each of theses five blood sampling, an average of 50 % of patients had Anti-Tat IgG, it turned out that 86% of patients could recognize Tat at least in one blood sampling during the course of the study. Amazingly, anti-Tat IgG appeared and/or disappeared in 66 % of patients. Only 20% had anti-Tat IgG remaining persistently while 14% were consistently without anti Tat IgG in the five blood sampling. No significant correlation was found between anti-Tat IgG and CD4+ T cell, CD8+ T cell and B cell counts revealing the incapacity of these anti Tat IgG to neutralize extra cellular Tat. Interestingly the absence and then the appearance of anti-Tat IgG in patients suggest the presence of HIV infected cells in the blood that may constitute a significant reservoir of HIV infected cells. As a conclusion antiretroviral therapy does not block the secretion of Tat and may explain why HIV infected cells can survive in spite of an effective ART treatment.
Keywords: Antibody, antiretroviral therapy, b cell, HIV, Tat, vaccine, cellular immunity, HIV infected cells, anti Tat IgG, patients
Infectious Disorders - Drug Targets
Title: Antiretroviral Therapy Does Not Block the Secretion of the Human Immunodeficiency Virus Tat Protein
Volume: 12 Issue: 1
Author(s): Catherine Tamalet, Erwann P. Loret, Grant R. Campbell, Stephen A. Spector, Philippe Brouqui, Andreas Stein, Francoise Dignat-George, Pascale Paul, Corinne Brunet, Sonia Mediouni, Herve Moreau, Malika Mokhtari, Herve Tissot-Dupont, Catherine Dhiver, Isabelle Ravaux, Gilbert Baillat and Albert Darque
Affiliation:
Keywords: Antibody, antiretroviral therapy, b cell, HIV, Tat, vaccine, cellular immunity, HIV infected cells, anti Tat IgG, patients
Abstract: Tat is a viral protein secreted from HIV infected cells and extra cellular Tat is suspected to prevent destruction of HIV infected cells from cells of the cellular immunity. The effect of anti retroviral therapy (ART) on Tat secretion has never been investigated. In this study, we tested for antibody reactivity against Tat variants representative of the main HIV subtypes in HIV positive patients receiving ART with undetectable viral loads ( < 40 copies/mL) over the course of one year with a blood sampling every three months. For each of theses five blood sampling, an average of 50 % of patients had Anti-Tat IgG, it turned out that 86% of patients could recognize Tat at least in one blood sampling during the course of the study. Amazingly, anti-Tat IgG appeared and/or disappeared in 66 % of patients. Only 20% had anti-Tat IgG remaining persistently while 14% were consistently without anti Tat IgG in the five blood sampling. No significant correlation was found between anti-Tat IgG and CD4+ T cell, CD8+ T cell and B cell counts revealing the incapacity of these anti Tat IgG to neutralize extra cellular Tat. Interestingly the absence and then the appearance of anti-Tat IgG in patients suggest the presence of HIV infected cells in the blood that may constitute a significant reservoir of HIV infected cells. As a conclusion antiretroviral therapy does not block the secretion of Tat and may explain why HIV infected cells can survive in spite of an effective ART treatment.
Export Options
About this article
Cite this article as:
Tamalet Catherine, P. Loret Erwann, R. Campbell Grant, A. Spector Stephen, Brouqui Philippe, Stein Andreas, Dignat-George Francoise, Paul Pascale, Brunet Corinne, Mediouni Sonia, Moreau Herve, Mokhtari Malika, Tissot-Dupont Herve, Dhiver Catherine, Ravaux Isabelle, Baillat Gilbert and Darque Albert, Antiretroviral Therapy Does Not Block the Secretion of the Human Immunodeficiency Virus Tat Protein, Infectious Disorders - Drug Targets 2012; 12 (1) . https://dx.doi.org/10.2174/187152612798994939
DOI https://dx.doi.org/10.2174/187152612798994939 |
Print ISSN 1871-5265 |
Publisher Name Bentham Science Publisher |
Online ISSN 2212-3989 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Determinants of Macromolecular Specificity from Proteomics-Derived Peptide Substrate Data
Current Protein & Peptide Science The Role of Natural Killer T Cells in Acute Kidney Injury: Angel or Evil?
Current Protein & Peptide Science Editorial [Hot Topic: Matrix Metalloproteinases in Cardiovascular Disease (Guest Editors: N. Papageorgiou & D. Tousoulis)]
Current Topics in Medicinal Chemistry Chronic Immune Activation Among Treatment Naïve HIV/ HBV Coinfected Individuals From Southern India
Current HIV Research Metabotropic Glutamate Receptors in Central Nervous System Diseases
Current Drug Targets CYP2C and CYP2B Mediated Metabolic Activation of Retrorsine in Cyp3a Knockout Mice
Current Drug Metabolism Cerebral White Matter Injuries Following a Hypoxic/Ischemic Insult During the Perinatal Period: Pathophysiology, Prognostic Factors, and Future Strategy of Treatment Approach. A Minireview
Current Pharmaceutical Design Pharmacogenetic Aspects of Therapy with Cholinesterase Inhibitors: The Role of CYP2D6 in Alzheimers Disease Pharmacogenetics
Current Alzheimer Research CYP4Z1 – A Human Cytochrome P450 Enzyme that Might Hold the Key to Curing Breast Cancer
Current Pharmaceutical Design Hemodynamic Forces Regulate Embryonic Stem Cell Commitment to Vascular Progenitors
Current Cardiology Reviews NOX3-Targeted Therapies for Inner Ear Pathologies
Current Pharmaceutical Design CCL21 and IFNγ Recruit and Activate Tumor Specific T cells in 3D Scaffold Model of Breast Cancer
Anti-Cancer Agents in Medicinal Chemistry Drug Targets from Human Pathogenic Amoebas: Entamoeba histolytica,Acanthamoeba polyphaga and Naegleria fowleri
Infectious Disorders - Drug Targets A Role for the Complement System in Rheumatoid Arthritis
Current Pharmaceutical Design Long Chain n-3 Polyunsaturated Fatty Acids in the Prevention of Allergic and Cardiovascular Disease
Current Pharmaceutical Design A Comprehensive Review of Soluble Epoxide Hyådrolase Inhibitors Evaluating their Structure-Activity Relationship
Mini-Reviews in Medicinal Chemistry Phytotherapy for the Prevention of Atherosclerosis-Associated Early Cerebral Ischemia
Current Drug Metabolism Editorial (Hot Topic: Novel Enzyme Targets of Folate Metabolism)
Current Enzyme Inhibition Inhibition of Hepatobiliary Transporters by A Novel Kinase Inhibitor Contributes to Hepatotoxicity in Beagle Dogs
Drug Metabolism Letters Potent, Nonpeptide Inhibitors of Human Mast Cell Tryptase. 2. Investigation of the Carboxamide Portion of Spirocyclic Piperidine Amides
Letters in Drug Design & Discovery